公开(公告)号：US20150175572A1

公开(公告)日：2015-06-25

申请号：US14642274

申请日：2015-03-09

Applicant: PFIZER INC.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  Indrawan James MCALPINE ,  Sacha NINKOVIC ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES ,  Luke Raymond ZEHNDER

IPC: C07D401/06 ,  C07D471/04 ,  C07D405/14 ,  C07D401/14 ,  C07D413/14

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及通式（I）的化合物，其中R1，R2，U，V，L，M，R5，m，X，Y和Z如本文所定义，及其药学上可接受的盐， 这些化合物和盐，以及使用这些化合物，盐和组合物用于治疗异常细胞生长（包括癌症）的方法。

公开(公告)号：US20170152239A1

公开(公告)日：2017-06-01

申请号：US15425732

申请日：2017-02-06

Applicant: PFIZER INC.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  Indrawan James MCALPINE ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES

IPC: C07D401/14 ,  C07D487/08 ,  C07D409/14 ,  C07D413/14 ,  C07D491/08 ,  C07D213/64 ,  C07D401/12 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D213/64 ,  C07D401/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D487/08 ,  C07D491/08

Abstract: This invention relates to compounds of general formula in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.

公开(公告)号：US20140179667A1

公开(公告)日：2014-06-26

申请号：US14132567

申请日：2013-12-18

Applicant: PFIZER INC.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  Indrawan James MCAPLINE ,  Sacha NINKOVIC ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES ,  Luke Raymond Zehnder

IPC: C07D401/06 ,  C07D487/04 ,  C07D401/14 ,  C07D471/04 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及其中R1，R2，U，V，L，M，R5，m，X，Y和Z如本文所定义的通式（I）化合物及其药学上可接受的盐， 这些化合物和盐，以及使用这些化合物，盐和组合物来治疗异常细胞生长（包括癌症）的方法。

公开(公告)号：US20250034173A1

公开(公告)日：2025-01-30

申请号：US18903345

申请日：2024-10-01

Applicant: PFIZER INC.

Inventor： Benjamin Joseph BURKE ,  Alexander BURTEA ,  Jacob Cole DEFOREST ,  Asako NAGATA ,  Simon Paul PLANKEN ,  Jillian Elyse SPANGLER ,  Scott Channing SUTTON ,  Hanna Maria WISNIEWSKA ,  Shouliang YANG

IPC: C07D519/00 ,  A61K31/553 ,  A61P35/00

Abstract: The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.

公开(公告)号：US20240294506A1

公开(公告)日：2024-09-05

申请号：US18346933

申请日：2023-07-05

Applicant: PFIZER INC.

Inventor： Douglas Carl BEHENNA ,  Kevin Daniel FREEMAN-COOK ,  Robert Louis HOFFMAN ,  Asako NAGATA ,  Sacha NINKOVIC ,  Scott Channing SUTTON

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)






and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20240336631A1

公开(公告)日：2024-10-10

申请号：US18625795

申请日：2024-04-03

Applicant: PFIZER INC.

Inventor： Benjamin Joseph BURKE ,  Alexander BURTEA ,  Jacob Cole DEFOREST ,  Asako NAGATA ,  Simon Paul PLANKEN ,  Jillian Elyse SPANGLER ,  Scott Channing SUTTON ,  Hanna Maria WISNIEWSKA ,  Shouliang YANG

IPC: C07D519/00 ,  A61K31/553 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61K31/553 ,  A61P35/00

Abstract: The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.

公开(公告)号：US20170233368A1

公开(公告)日：2017-08-17

申请号：US15585880

申请日：2017-05-03

Applicant: Pfizer Inc.

Inventor： Martin Paul EDWARDS ,  Robert Arnold KUMPF ,  Pei-Pei KUNG ,  lndrawan James MCALPINE ,  Sacha NINKOVIC ,  Eugene Yuanjin RUI ,  Scott Channing SUTTON ,  John Howard TATLOCK ,  Martin James WYTHES ,  Luke Raymond ZEHNDER

IPC: C07D401/06 ,  C07D487/04 ,  C07D405/14 ,  C07D471/04 ,  C07D401/14 ,  C07D413/14

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20150203502A1

公开(公告)日：2015-07-23

申请号：US14675527

申请日：2015-03-31

Applicant: PFIZER INC.

Inventor： Hengmiao CHENG ,  Theodore Otto JOHNSON, JR. ,  John Charles KATH ,  Kevin Kun-Chin LIU ,  Elizabeth Ann LUNNEY ,  Asako NAGATA ,  Sajiv Krishnan NAIR ,  Simon Paul PLANKEN ,  Scott Channing SUTTON

IPC: C07D487/04 ,  C07D473/18 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D473/18 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中Q，T，V，W，X，Y，Z，环A，R1，R2，R3，R4，R5，R5a，R6，R7 ，R 8，R 9，R 10，R 11，R 12，R 13，R 14，R 15，R 16，R 17和m如本文所定义。 有新的吡咯并嘧啶和嘌呤衍生物可用于哺乳动物治疗异常细胞生长，如癌症。 另外的实施方案涉及含有化合物的药物组合物和使用化合物和组合物治疗哺乳动物异常细胞生长的方法。